Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon

Table 1

Molecular breast cancer subtypes based on St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Intrinsic subtype	Clinicopathologic interpretation
	ER and/or PgR	HER2	Ki67 expression
Lumina A type	Positive	Negative	≤14%
Luminal B type	Positive	Negative	≥ 14%
Luminal B HER2 type	Positive	Positive	≤14% or ≥ 14%
HER2 overexpression type	Negative	Positive	≤14% or ≥ 14%
Triple negative type	Negative	Negative	≤14% or ≥ 14%